|
Prevention Research Coordinating Committee (PRCC)
|
Committee, Work group, Advisory group, or Task Force
|
AHRQ, ATSDR, CDC, OS
|
OD/OSP, CC, CIT, CSR, FIC, NCATS, NCCAM, NCI, NEI, NHGRI, NHLBI, NIA, NIAAA, NIAID, NIAMS, NIBIB, NICHD, NIDA, NIDCD, NIDCR, NIDDK, NIEHS, NIGMS, NIMH, NIMHD, NINDS, NINR, NLM, OD/DPCPSI/OAR, OD/DPCPSI/OBSSR, OD/DPCPSI/ODP, OD/DPCPSI/ORWH, OD/OLPA
|
The NIH Prevention Research Coordinating Committee (PRCC) serves as a venue for exchanging programmatic and scientific information of interest to the NIH, as well as for planning and implementation of collaborative activities. The PRCC promotes prevention research designed to yield results directly applicable to identifying and assessing risk, and to developing interventions for preventing or ameliorating high-risk behaviors and exposures, the occurrence of disease/disorder/injury, or the progression of detectable but asymptomatic disease. Prevention research also includes research studies to develop and evaluate disease prevention and health promotion recommendations and public health programs.
|
|
Prevention Scientists Promoting Global Health: Emerging Visions for Today and Tomorrow
|
Meeting/ Workshop
|
CDC
|
NIAAA, NCI, NHLBI, NICHD, NIDA, NIMH
|
The Society for Prevention Research envisions a wellness-oriented society in which evidenced-based programs and policies are continuously applied to improve the health and well being of its citizens. The SPR Annual Meeting provides unique opportunities to advance this vision by providing an integrated forum for: the exchange of new concepts, methods, and results from prevention and public health-related research; and communication between scientists, public policy leaders and practitioners concerning the implementation of evidence-based preventive interventions.
|
|
Prevention with Positives Intervention HIV Clinics (Y01-MH-1318)
|
Research Initiative
|
CDC
|
NIMH, NIAID
|
The Prevention with Positives Intervention HIV Clinics is a contract with the CDC to conduct an HIV clinic-based comparison of a comprehensive prevention program for people living with HIV targeting multiple health behaviors (sexual risk, medication adherence, clinic attendance) and health outcomes (viral load, retention in care).
|
|
Profiling of Compounds Against Isolates of Cryptcoccus galti & C. neoformans
|
Research Initiative
|
CDC
|
NCATS
|
Test compounds against isolates of C. gattii and C. neoformans. The panel of isolates consists of 300 genotyped isolates of C. gattii from all over the world and 100 isolates of C. neoformans which originated in South Africa. Each isolate would be tested once following the broth microdilution protocol as outlined in the Clinical and Laboratory Standards (CL5I) document M27-A3 (Clincal Laboratory Standards Institute, 2008). All isolates tested would already have fluconazole Minimum Inhibitor Concentration (MIC) data available for comparison.
|
|
Public Health and Emergency Medical Countermeasures Enterprise (PHEMCE)
|
Other
|
ACF, CDC, FDA, OS, SAMHSA
|
OD/OSP, NIAID, NIAMS, NICHD, NINDS, NLM
|
The Public Health Emergency Medical Countermeasures Enterprise (PHEMCE) determines the various Medical Countermeasures (MCMs) that are needed and oversees their development and procurement. The PHEMCE also advances national preparedness against chemical, biological, radiological, nuclear (CBRN) and emerging infectious disease (EID) threats, including pandemic influenza, by coordinating medical countermeasure related efforts within HHS and in cooperation with interagency PHEMCE partners. In order to accomplish this objective, the PHEMCE uses a multitier approach. Each tier comprises multiple agencies within HHS and/ or DHS that work together in a collaborative fashion to further the preparedness of the nation. The first tier includes the Biological, Chemical, Radiological/Nuclear Working Groups; the Blood/Tissue MCM Requirements Working Group; and Integrated Program Teams (IPTs). The Working Groups (WG) utilize scenario-based analyses to determine which medical countermeasures are needed for the SNS, or affiliated repositories. The IPTs provide an end-to-end vision of medical countermeasures needed for a particular threat type (e.g., anthrax, rad/nuc, etc.). The scope of their work includes setting requirements for the stockpiling of MCMs, MCM delivery and dispensing and monitoring MCM development. The IPTs also advise the Enterprise Executive Committee as to threat- or capability-specific MCM priorities for improving preparedness, to inform leadership consideration of cross-threat prioritizations and strategic goal setting. Agencies represented on the PHEMCE WGs and IPTs include; National Institute of Health(NIH), Centers for Disease Control and Prevention (CDC), Food and Drug Administration (FDA), Department of Defense (DOD), Assistant Secretary for Preparedness and Response (ASPR), Biomedical Advanced Research and Development Authority (BARDA), Department of Homeland Security (DHS) and the Department of Veterans Affairs (VA). The second tier of this process is the Enterprise Executive Committee (EEC). The EEC is comprised of senior program managers across the partner agencies. It provides the critical interface and organizing capability between the strategic focus of the Enterprise Senior Council (ESC) and the tactical-level efforts conducted within the subordinate IPTs and WGs. This committee serves as a Senior Advisor-level coordination mechanism across the federal agencies involved in PHEMCE-related activities to facilitate vetting and prioritization of policy decision materials to be presented to the ESC. The third and most senior tier of the PHEMCE and the forum for cooperation and overall mission fulfillment is the Enterprise Senior Council (ESC). Structurally, the ESC is led by the Assistant Secretary for Preparedness and Response and comprised of the senior leadership of National Institute of Allergy and Infectious Disease (NIAID) within the National Institutes of Health (NIH), Centers for Disease Control and Prevention (CDC), and Food and Drug Administration (FDA) with comparable senior level representatives from the Department of Defense (DoD) , the Department of Homeland Security (DHS), the Department of Veterans Affairs (VA) , and the U.S. Department of Agriculture (USDA) As the most senior level in the PHEMCE structure, this group approves major policies, product requirements, and large-scale procurement actions. It also oversees strategic reviews of the activities in each of the major threat portfolios (e.g., anthrax, smallpox, rad/nuc) and is the final reporting body for high priority actions identified as gaps in these reviews.
|
|
Public Health Dimensions of Epilepsy
|
Other
|
ACF, CDC, FDA, OS
|
NINDS, NIA, NICHD, NIMH
|
The Institute of Medicine convened an ad hoc committee to recommend priorities in public health, healthcare and human services, and health literacy and public awareness for the epilepsies and to propose strategies to address these priorities. The committee''s report was published March 30, 2012: http://www.iom.edu/Reports/2012/Epilepsy-Across-the-Spectrum.aspx.
|
|
Public Health Emergency Medical Countermeasures Enterprise (PHEMCE) Blood and Tissue Product Requirements Working Group
|
Meeting/ Workshop
|
CDC, FDA, OS
|
NIAID
|
This Working Group coordinates requirements, needs, and research and development directions for blood and tissue products for mass casualty treatment after a radiation emergency.
|
|
Public Health Emergency Medical Countermeasures Enterprise (PHEMCE) Chemical Integrated Product Development Team (IPT)
|
Committee, Work group, Advisory group, or Task Force
|
CDC, FDA, OS
|
NINDS, NIAID
|
The HHS Public Health Emergency Medical Countermeasures Enterprise (HHS PHEMCE) leads the mission to develop and acquire medical countermeasures that will improve public health emergency preparedness as well as prevent and mitigate the adverse health consequences associated with chemical, biological, radiological and nuclear (CBRN), and naturally occurring threats.
|
|
Public Health Emergency Medical Countermeasures Enterprise (PHEMCE) Chemical Requirements Working Group
|
Committee, Work group, Advisory group, or Task Force
|
CDC, FDA, OS
|
NINDS, NIAID, NICHD, NIEHS
|
The HHS Public Health Emergency Medical Countermeasures Enterprise (HHS PHEMCE) leads the mission to develop and acquire medical countermeasures that will improve public health emergency preparedness as well as prevent and mitigate the adverse health consequences associated with chemical, biological, radiological and nuclear (CBRN), and naturally occurring threats.
|
|
Public Health Prevention of HIV Risk Behaviors Technical Working Group
|
Committee, Work group, Advisory group, or Task Force
|
CDC, SAMHSA
|
NIAAA, NIDA
|
Collaboration with the Office of Global AIDS Coordination (OGAC), CDC to identify and implement effective HIV prevention and treatment interventions among alcohol abusing and dependent populations.
|